Communiqués Cardiol Therapeutics Inc.

Actions

CRDL

CA14161Y2006

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. Autres places de cotation 22:27:07 02/07/2026			Varia. 5j.	Varia. 1 janv.
1,540 ^CAD	+3,36%		+1,99%	+17,56%

11/05	Cardiol Therapeutics Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
07/05	Cardiol Therapeutics Inc annonce l'acceptation des résultats de phase II Maveric pour publication dans le Journal of the American Heart Association	CI

Communiqués

25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	PR
25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders	AQ
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	PR
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT	AQ
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	PR
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ	AQ
07/05	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	PR
07/05	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association	AQ
28/04	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	PR
28/04	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program	AQ
14/04	Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart	NE
01/04	Cardiol Therapeutics Announces Year-End 2025 Update on Operations	NE
25/02	Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference	NE
10/02	Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure	NE
23/01	Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million	NE
16/01	Canadian Investment Regulatory Organization Trade Resumption - CRDL	AQ
16/01	Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million	NE
16/01	Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million	NE
16/01	Canadian Investment Regulatory Organization Trading Halt - CRDL	AQ
13/01	Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis	NE
01/12	New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions	NE
13/11	Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040	NE
05/11	Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases	NE
21/10/25	Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027	NE
20/10/25	Canadian Investment Regulatory Organization Trade Resumption - CRDL	AQ